By 2013, Poirier et al.’s research on Seneca Valley Virus (SVV-001) introduced a novel classification method, demonstrating that the ratio of ASCL1 to NEUROD1 genes could effectively predict SCLC’s response to SVV-001 treatment (16). This evidence concerns the gene NEUROD1 and small cell lung carcinoma.